Update on Writ Petitions

Summary by AI ^BETAClose X

Beximco Pharmaceuticals PLC has announced that the High Court Division of the Supreme Court of Bangladesh will hear its outstanding Writ Petitions after the court's vacation, which runs from March 15 to April 18, 2026. These petitions challenge the Bangladesh Securities and Exchange Commission's proposed appointment of nine additional independent non-executive directors to the Company's Board and the BSEC's order to hold a Board Meeting to onboard these directors.

Disclaimer*

Beximco Pharmaceuticals PLC

05 March 2026

5 March 2026

BEXIMCO PHARMACEUTICALS PLC.

Update on Writ Petitions

Beximco Pharmaceuticals PLC. ("the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, provides an update regarding the timeline for its outstanding Writ Petitions to be heard by the High Court Division of the Supreme Court of Bangladesh.

Further to previous announcements, the hearing of Writ Petition No. 525 of 2025 (challenging the proposed appointment by the Bangladesh Securities and Exchange Commission of nine additional independent non-executive directors to the Company's Board) and Writ Petition No. 1243 of 2026 (challenging the BSEC's order to hold a Board Meeting onboarding the nine additional independent directors) will now commence after the scheduled vacation (from 15 March 2026 to 18 April 2026) of the High Court Division of the Supreme Court of Bangladesh.

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext. 20030

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: +880 2 41060531, Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

FTI Consulting

Simon Conway / Sam Purewal

Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals PLC

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END